The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor is a transcription factor that mediates varied cellular responses. The C terminus of p53 is subjected to multiple and diverse post-translational modifications. An attractive hypothesis is that differing sets of combinatorial modifications therein determine distinct cellular outcomes. To address this in vivo, a Trp53 ΔCTD/ΔCTD mouse was generated in which the endogenous p53 is targeted and replaced with a truncated mutant lacking the C-terminal 24 amino acids. These Trp53 ΔCTD/ΔCTD mice die within 2 wk post-partum with hematopoietic failure and impaired cerebellar development. Intriguingly, the C terminus acts via three distinct mechanisms to control p53-dependent gene expression depending on the tissue. First, in the bone marrow and thymus, the C terminus dampens p53 activity. Increased senescence in the Trp53 ΔCTD/ΔCTD bone marrow is accompanied by up-regulation of Cdkn1 (p21). In the thymus, the C-terminal domain negatively regulates p53-dependent gene expression by inhibiting promoter occupancy. Here, the hyperactive p53 ΔCTD induces apoptosis via enhanced expression of the proapoptotic Bbc3 (Puma) and Pmaip1 (Noxa). In the liver, a second mechanism prevails, since p53 ΔCTD has wild-type DNA binding but impaired gene expression. Thus, the C terminus of p53 is needed in liver cells at a step subsequent to DNA binding. Finally, in the spleen, the C terminus controls p53 protein levels, with the overexpressed p53 ΔCTD showing hyperactivity for gene expression. Thus, the C terminus of p53 regulates gene expression via multiple mechanisms depending on the tissue and target, and this leads to specific phenotypic effects in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Cell-based studies initially demonstrated that the p53 C-terminal lysines are required for this process (Kubbutat et al. 1997, 1998).”
BackgroundBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 3×
“The p53 protein is kept inactive through interactions with several negative regulators, most notably Mdm2 (Luo et al. 2004; Kruse and Gu 2009; Vousden and Prives 2009; Manfredi 2010).”
BackgroundMethodTumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · cited 11×
“It has been proposed that post-translational modifications of p53 are critical to disrupt its binding to Mdm2 and facilitate its interaction with cofactors, resulting in a p53 protein that is robust in its ability to transcriptionally regulate target gene expression (Kruse and Gu 2009; Manfredi 2010).”
BackgroundMethodInfluentialHematopoietic Stem Cell Quiescence Maintained by p21 cip1/waf1
Cheng, T., Rodrigues, N., Shen, H., Yang, Y.-G., Dombkowski, D., Sykes, M., & Scadden, D. T. (2000) · Science · doi:10.1126/science.287.5459.1804 · Cited by 1,339
Suppression of induced pluripotent stem cell generation by the p53–p21 pathway
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., & Yamanaka, S. (2009) · Nature · doi:10.1038/nature08235 · Cited by 1,301 · cited 1×
“These results are substantiated by other studies that have proposed that p53 counteracts stem cell reprogramming by activating a senescencepromoting stress response (Hong et al. 2009; Utikal et al. 2009).”
ResultWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 1×
“The p53 tumor suppressor is a critical mediator of the cellular response to stress and is mutated in >50% of human tumors (Brosh and Rotter 2009).”
BackgroundHematopoiesis: a human perspective
Doulatov, S., Notta, F., Laurenti, E., & Dick, J. E. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.01.006 · Cited by 895
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767 · cited 2×
“…to spontaneous cancers (mainly lymphomas and sarcomas) within 6–9 mo after birth (Donehower et al. 1992; Jacks et al. 1994). p53 has also been implicated in stem cell maintenance and homeostasis (Zheng et al. 2008; Cicalese et al. 2009; Liu et al. 2009; Spike and Wahl 2011; Bonizzi et al. 2012).”
BackgroundChen, X., Ko, L. J., Jayaraman, L., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.19.2438 · Cited by 735
Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710 · cited 3×
“These supported a role in tracking of p53 on genomic DNA (McKinney et al. 2004; Kruse and Gu 2009; Carvajal and Manfredi 2013) as well as serving as recruitment sites for transcriptional cofactors (Barlev et al. 2001; Mujtaba et al. 2004).”
BackgroundThe Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells
Cicalese, A., Bonizzi, G., Pasi, C. E., Faretta, M., Ronzoni, S., Giulini, B., Brisken, C., Minucci, S., Di Fiore, P. P., & Pelicci, P. G. (2009) · Cell · doi:10.1016/j.cell.2009.06.048 · Cited by 696
p53 Regulates Hematopoietic Stem Cell Quiescence
Liu, Y., Elf, S. E., Miyata, Y., Sashida, G., Liu, Y., Huang, G., Di Giandomenico, S., Lee, J. M., Deblasio, A., Menendez, S., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2008.11.006 · Cited by 547 · cited 5×
“One of these regulators (Gfi1) was previously shown to be a direct p53 target gene involved in the maintenance of HSC quiescence in a p53-dependent manner (Liu et al. 2009).”
BackgroundResultInfluentialGfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells
Hock, H., Hamblen, M. J., Rooke, H. M., Schindler, J. W., Saleque, S., Fujiwara, Y., & Orkin, S. H. (2004) · Nature · doi:10.1038/nature02994 · Cited by 541 · cited 2×
“The expression pattern of Gfi1 and Gfi1b, two essential regulators of hematopoiesis (Hock et al. 2004; van der Meer et al. 2010), is highly restricted to hematopoietic organs (Tong et al.”
BackgroundMDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · cited 1×
“The data here raise concerns about the use of therapeutic approaches based on small molecules that disrupt the Mdm2–p53 interaction (Vassilev 2007).”
BackgroundThe power and the promise of oncogene-induced senescence markers
Collado, M., & Serrano, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1884 · Cited by 404 · cited 2×
“…mRNA levels of several bona fide senescence markers were measured by qRT–PCR. Cdkn1a (p21) and Cdkn2b (p15INK4b), two potent cell cycle inhibitors that have been shown to be overexpressed in senescent cells (Collado and Serrano 2006), were up-regulated in the mutant bone marrow cells (Fig.”
BackgroundMethodThe Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344 · cited 2×
“…has been proposed that post-translational modifications of p53 are critical to disrupt its binding to Mdm2 and facilitate its interaction with cofactors, resulting in a p53 protein that is robust in its ability to transcriptionally regulate target gene expression (Kruse and Gu 2009; Manfredi 2010).”
BackgroundSelf-citationEspinosa, J. M., Verdun, R. E., & Emerson, B. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00359-9 · Cited by 256 · cited 1×
“The remainder of the protocol was previously described (Carvajal et al. 2012) and adapted from Espinosa et al. (2003) using Protein A Dynabeads (Invitrogen) for the pull-down.”
MethodFeng, L., Lin, T., Uranishi, H., Gu, W., & Xu, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5389-5395.2005 · Cited by 236 · cited 2×
“Previous reports of C-terminal Trp53K6R and Trp537KR mice in which six or seven lysines have been mutated to arginines failed to show any significant phenotype compared with wild type (Feng et al. 2005; Krummel et al. 2005).”
BackgroundResultKrummel, K. A., Lee, C. J., Toledo, F., & Wahl, G. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503068102 · Cited by 187 · cited 2×
“Previous reports of C-terminal Trp53K6R and Trp537KR mice in which six or seven lysines have been mutated to arginines failed to show any significant phenotype compared with wild type (Feng et al. 2005; Krummel et al. 2005).”
BackgroundResultCarvajal, L. A., Hamard, P.-J., Tonnessen, C., & Manfredi, J. J. (2012) · Genes & Development · doi:10.1101/gad.184911.111 · Cited by 151 · cited 1×
“The remainder of the protocol was previously described (Carvajal et al. 2012) and adapted from Espinosa et al. (2003) using Protein A Dynabeads (Invitrogen) for the pull-down.”
MethodSelf-citationAnother fork in the road—life or death decisions by the tumour suppressor p53
Carvajal, L. A., & Manfredi, J. J. (2013) · The EMBO Reports · doi:10.1038/embor.2013.25 · Cited by 149 · cited 5×
“Experiments in cell culture were more in line with a positive role for the C terminus (Chen et al. 1996; Kruse and Gu 2009; Hamard et al. 2012; Carvajal and Manfredi 2013).”
BackgroundInfluentialSelf-citationHaploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development
Terzian, T., Wang, Y., Van Pelt, C. S., Box, N. F., Travis, E. L., & Lozano, G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00555-06 · Cited by 116 · cited 3×
“Similarly, p53 has been implicated in brain development (Liu et al. 2007; Terzian et al. 2007; Malek et al. 2011; Mendrysa et al. 2011).”
BackgroundResultWang, Y. V., Leblanc, M., Fox, N., Mao, J.-H., Tinkum, K. L., Krummel, K., Engle, D., Piwnica-Worms, D., Piwnica-Worms, H., Balmain, A., et al. (2011) · Genes & Development · doi:10.1101/gad.2024411 · Cited by 53
Cited by
The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
“PTM mutant mice may exhibit positive or negative regulation of p53 activity.(363,364) Thus, future research will further understand the specific role of each PTM and how modification can be used as a therapeutic target for cancer.”
BackgroundMechanisms of transcriptional regulation by p53
Sullivan, K. D., Galbraith, M. D., Andrysik, Z., & Espinosa, J. M. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.174 · Cited by 446
Structural Evolution and Dynamics of the p53 Proteins
Chillemi, G., Kehrloesser, S., Bernassola, F., Desideri, A., Dötsch, V., Levine, A. J., & Melino, G. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028308 · Cited by 65
Metadata
- Authors
- Hamard, P.-J., Barthelery, N., Hogstad, B., Mungamuri, S. K., Tonnessen, C. A., Carvajal, L. A., Senturk, E., Gillespie, V., Aaronson, S. A., Merad, M., & Manfredi, J. J.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2013-09-01
- Volume
- 27
- Issue
- 17
- Pages
- 1868-1885
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2143728695
- Cited by
- 74
- References
- 24
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.